Drug Profile
MAb 4 - Zydus Cadila
Alternative Names: MAb4Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in India (Parenteral)
- 21 Oct 2015 Clinical trials in Cancer in India (Parenteral) (Zydus presentation, May 2015)